Bugworks Research

Saratoga, United States Founded: 2014 • Age: 12 yrs
Drugs for antibiotic-resistant infections and cancer are developed.
Annual revenue $3.3M Latest available
Total funding $42.9M 15 rounds
Employees - Tracked headcount
Investors 20 Known backers
Products 2 Services tracked
Competitors 8 Brand Intelligence

About Bugworks Research

Bugworks Research is a company based in Saratoga (United States) founded in 2014 by Santanu Datta and Anand Anandkumar. Bugworks Research has raised $42.89 million across 15 funding rounds from investors including NIH, Baxter and 3one4 Capital. Bugworks Research offers products and services including Antibacterial Agents and Oncology Therapeutics. Bugworks Research operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

  • Headquarter Saratoga, United States
  • Founders Santanu Datta, Anand Anandkumar
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Bugworks Research India Private Limited
  • Date of Incorporation 04 Feb, 2014
  • Jurisdiction Bangalore, Karnataka, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $3.34 M (USD)
    39.83
    as on Mar 31, 2023
  • Net Profit
    $325.47 K (USD)
    -1
    as on Mar 31, 2023
  • EBITDA
    $987.21 K (USD)
    26.61
    as on Mar 31, 2023
  • Total Equity Funding
    $42.89 M (USD)

    in 15 rounds

  • Latest Funding Round
    $6.78 M (USD), Series B

    Feb 22, 2024

  • Investors
    NIH

    & 19 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Bugworks Research

Bugworks Research offers a comprehensive portfolio of products and services, including Antibacterial Agents and Oncology Therapeutics.

Product name locked
Category locked
Primary

Novel small molecules targeting multidrug-resistant infections.

Product name locked
Category locked
Locked

Small molecules for hypoxic and refractory solid tumors.

People of Bugworks Research

Headcount 10-50
Employee Profiles 19
Board Members and Advisors 8
Employee Profiles
People
Samba Siva Reddy V
Principal Scientist
People
Rajesh Kumar R.
Senior Scientist
People
John F. Tomayko
CMO
People
rashmi naik
Associate Research Scientist

Unlock access to complete

Board Members and Advisors
people
Vis Niranjan
Advisor
people
William Hope
Advisor
people
Satoshi Murakami
Advisor
people
Atsushi Usami
Executive Director

Unlock access to complete

Funding Insights of Bugworks Research

Bugworks Research has successfully raised a total of $42.89M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $6.78 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Bugworks Research

Bugworks Research has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, Baxter and 3one4 Capital.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Venture capital investments in technology sectors like SaaS and Fintech in India.
Locked Locked Locked
Global Brain is recognized as a venture capital firm supporting startups.
Locked Locked Locked
Seed and Early stage VC firm investing in Japan
Locked Locked Locked
Premium access

Investor details for Bugworks Research

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Bugworks Research

Investments
Premium access

Investment portfolio details for Bugworks Research

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Bugworks Research

Premium access

Detailed financials for Bugworks Research

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Bugworks Research Comparisons

Bugworks Research Primary company
Description
Drugs for antibiotic-resistant infections and cancer are dev...
Location
Saratoga, United States
Founded Year
2014
Annual Revenue
$3.34 M (USD)
Net Profit
$325.47 K (USD)
EBITDA
$987.21 K (USD)
Employees
Not available
Premium access

Peer comparison for Bugworks Research

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Bugworks Research

Bugworks Research operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Locked Locked Locked
MicroRNA-based therapeutics are developed for treating multiple diseases.
Locked Locked Locked
Therapeutics for cancer and rare diseases are developed.
Premium access

Detailed competitors of Bugworks Research

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Bugworks Research

Premium access

Complete news archive for Bugworks Research

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bugworks Research

Bugworks Research was founded in 2014.

Bugworks Research is headquartered in Saratoga, United States. It is registered at Saratoga, California, United States.

Anand Anandkumar is the current CEO of Bugworks Research. They have also founded this company.

Bugworks Research is a funded company, having raised a total of $42.89M across 15 funding rounds to date.

Annual revenue of Bugworks Research is $3.34M as on Mar 31, 2023.

Bugworks Research was founded in 2014 in Saratoga, United States, within the biotechnology sector. Therapeutics targeting antibiotic-resistant bacterial infections and cancer are developed using the Microbial Platform (BMP), which models biofilm formation and bacterial behavior. A lead Gyrase-topoisomerase inhibitor is advanced for intravenous and oral treatments of multi-drug resistant infections, with mechanisms that inhibit two replication targets and circumvent bacterial efflux resistance.

Bugworks Research's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

Bugworks Research offers Antibacterial Agents and Oncology Therapeutics.

Bugworks Research has 20 investors. Key investors include NIH, Baxter, 3one4 Capital, CARB-X, and UK Research and Innovation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available